In April, an ejection seat manufacturer officially notified the Naval Surface Warfare Center Indian Head Division (NSWC IHD) Cartridge Actuated Devices/Propellant Actuated Devices (CAD/PAD) Joint ...

During the month of May, the Cartridge and Propellant Actuated Device (CAD/PAD) Joint Program supported two workshops sponsored by NAVAIR's Program Management Air (PMA) 201 at the College of Southern ...

Patients who have both coronary and peripheral artery disease experience consistent reductions in ischemic complications after coronary stent placement when treated with extended dual antiplatelet ...

US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD). US regulators have ...

Please provide your email address to receive an email when new articles are posted on . The Foundation to Advance Vascular Cures has launched a new virtual educational resource directed at medical ...

Smoking adversely affects cardiovascular risk factors, affects inflammation, and is linked with atherosclerosis, but whether the smoking-atherosclerosis relationship is mediated through traditional ...

Rivaroxaban is the first and only non–vitamin K antagonist oral anticoagulant with this indication, the company said in a news release. The European Commission approved a regimen of rivaroxaban plus ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease who underwent revascularization, those with concomitant clinical ...

When peripheral artery disease (PAD) is known to accompany coronary artery disease (CAD) in people with diabetes, their already elevated risk of peripheral ischemic events rises even further. But so ...

Janssen announced that the Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) ...